AR059886A1 - Derivados de amidas como inhibidores de renina - Google Patents
Derivados de amidas como inhibidores de reninaInfo
- Publication number
- AR059886A1 AR059886A1 ARP070100947A ARP070100947A AR059886A1 AR 059886 A1 AR059886 A1 AR 059886A1 AR P070100947 A ARP070100947 A AR P070100947A AR P070100947 A ARP070100947 A AR P070100947A AR 059886 A1 AR059886 A1 AR 059886A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- ch2ch2
- ch2ch2ch2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de la Formula (1) donde X representa CH, N, o N+-O-; W representa un fenilo para-sustituido, un piridilo para-sustituido, o un tiazolilo; V representa -CH2CH2CH2-, -CH2CH2-A-, -CH2-A-CH2-, -A-CH2CH2-, -CH2CH2CH2CH2-, - A-CH2CH2CH2-, -CH2-A-CH2CH2-, -CH2CH2-A-CH2-, -CH2CH2CH2-A-, -A-CH2CH2-B-, CH2CH2CH2CH2CH2-, -A-CH2CH2CH2CH2-, -CH2-A-CH2CH2CH2-, -CH2CH2-A-CH2CH2, -CH2CH2CH2-A-CH2-, -CH2CH2CH2CH2-A-, -A-CH2CH2CH2-B-, CH2-A-CH2CH2-B-, -A-CH2CH2-B-CH2-, -A-CH2CH2CH2- B-CH2-, -CH2-A-CH2CH2CH2-B-, o -O-CH2-Q-, donde Q está ligado al grupo U de Formula 1, o V representa un pirrodinilo de la Formula (2); U representa arilo no sustituido; arilo mono-, di-, tri- o tetra-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo-C1-7, -CF3, halogeno, e hidroxi-alquilo-C1-7; o heteroarilo de cinco miembros con dos heteroátomos seleccionados independientemente entre nitrogeno, oxígeno y azufre, donde dicho radical heteroarilo está opcionalmente mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo-C1-7, alcoxi-C1-7, -CF3, -OCF3, y halogeno; Q representa un heteroarilo de cinco miembros con dos o tres heteroátomos seleccionados independientemente entre O y N; L representa -CH2-CH2-, -CH2-CH(R6)-CH2-, -CH2-N(R7)-CH2-, -CH2-O-CH2-, o -CH2-S-CH2-; A y B representan independientemente uno del otro -O- o -S-; R1 representa alquilo-C1-7 o cicloalquilo; R2 representa halogeno o alquilo-C1-7; R3 representa hidrogeno, halogeno, alquilo-C1-7, alcoxi-C1-7, o -CF3; R4 representa hidrogeno; alquilC1-7-O-(CH2)0-4-CH2-; CF3-O-(CH2)0-4-CH2-; R'2N-(CH2)0-4-CH2-, donde R' se selecciona independientemente del grupo formado por hidrogeno, alquilo-C1-7 (opcionalmente sustituido con uno a tres fluor), ciclopropilo (opcionalmente sustituido con uno a tres fluor), ciclopropil-alquilo-C1-7 (opcionalmente sustituido con uno a tres fluor), y -C(=O)-R'' donde R'' es alquiloC1-4, alcoxiC1-4, -CF3, -CH2-CF3, o ciclopropilo; o R13-C(=O)-(O)0-1-(CH2)0-4, donde R13 es alquiloC1-4, alcoxiC1-4, o ciclopropilo; donde R' y R'' preferiblemente no representan hidrogeno al mismo tiempo; R5 representa hidroxi, alcoxi-C1-7, hidroxi-alquilo-C1-7, dihidroxi-alquilo-C1-7, dihidroxi-alquilo-C1-7, alcoxi-C1-7-alquilo-C1-7, alcoxi-C1-7-alcoxi-C1-7-alquilo-C1-7, hidroxi-alcoxi-C1-7-alquilo-C1-7, carbamoil-alcoxi-C1-7, o alquilC1-7-carboniloxi; R6 representa -H, -CH2OR9, -CH2NR8R9, -CH2NR8COR9, -CH2NR8SO2R9, -CO2R9, -CH2OCONR8R9, -CONR8R9, -CH2NR8CONR8'R9, -CH2SO2NR8R9, -CH2SR9, -CH2SOR9, o -CH2SO2R9; R7 representa -R9, -COR9, -COOR11, -CONR8R9, -C(NR8)NR8'R9, -CSNR8R9, CSNR8R9, -SO2R9, o - SO2NR8R9; o R7 representa un radical de la Formulas (3) donde T representa -CH2-, -NH- o -O-, r es un numero entero entre 1 y 6 y s es un numero entero entre 1 y 4; R8 y R8' representan independientemente hidrogeno, alquilo-C1-7, alquenilo.C2-7, cicloalquilo, o cicloalquil-alquilo-C1-7, donde alquilo-C1-7, cicloalquilo, y cicloalquil-alquilo-C1-7 pueden estar sustituidos con uno, dos, o tres halogenos; R9 representa hidrogeno, alquilo-C1-7, cicloalquilo, o cicloalquil-alquilo-C1-7, donde alquilo-C1-7, cicloalquilo, y cicloalquil-alquilo-C1-7 pueden estar mono-, di- o tri-sustituidos, donde los sustituyentes se seleccionan independientemente del grupo formado por halogeno, hidroxi, -OCOR12, -COOR12, alcoxi-C1-7, ciano, SO2R12, - CONR12R12', morfolin-4-il-co-, ((4-alquilC1-7)piperazin-1-il)-CO-, -NHC(NH)NH2, -NR10R10' y alquilo-C1-7, con la condicion de que un átomo de carbono esté ligado a lo sumo a un heteroátomo en caso de que este átomo de carbono esté sp3-hibridizado; R10 y R10' representan independientemente hidrogeno, alquilo-C1-7, cicloalquilo, cicloalquil-alquilo-C1-7, hidroxi, alquilo-C1-7, -COOR8, o -CONH2; R11 representa halogeno, alquilo-C1-7, alcoxi-C1-7, -CF3, o hidrogeno; R12 y R12' representan independientemente hidrogeno, alquilo-C1-7, alquenilo-C2-7, cicloalquilo, o cicloalquil-alquilo-C1-7, donde alquilo-C1-7, cicloalquilo, y cicloalquil-alquilo-C1-7 pueden estar sustituidos con uno, dos, o tres halogenos; n representa el numero entero 0 o 1; y m representa el numero entero 0 o 1, con la condicion de que m representa el numero entero 1 si n representa el numero entero 1; y a sales de los mismos. También comprende aspectos relacionados que incluyen procesos para la preparacion de los compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos y especialmente su uso como inhibidores de renina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006050724 | 2006-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059886A1 true AR059886A1 (es) | 2008-05-07 |
Family
ID=38475245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100947A AR059886A1 (es) | 2006-03-08 | 2007-03-07 | Derivados de amidas como inhibidores de renina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090062342A1 (es) |
| EP (1) | EP1994026A2 (es) |
| JP (1) | JP2009529033A (es) |
| KR (1) | KR20090008211A (es) |
| CN (1) | CN101395149A (es) |
| AR (1) | AR059886A1 (es) |
| AU (1) | AU2007224368A1 (es) |
| BR (1) | BRPI0708567A2 (es) |
| CA (1) | CA2642436A1 (es) |
| CL (1) | CL2007000595A1 (es) |
| IL (1) | IL193885A0 (es) |
| MA (1) | MA30296B1 (es) |
| MX (1) | MX2008011340A (es) |
| NO (1) | NO20084186L (es) |
| NZ (1) | NZ571595A (es) |
| TW (1) | TW200800897A (es) |
| WO (1) | WO2007102127A2 (es) |
| ZA (1) | ZA200808540B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010323B (zh) * | 2004-08-25 | 2010-06-16 | 埃科特莱茵药品有限公司 | 作为肾素抑制剂的双环壬烯衍生物 |
| GEP20115206B (en) * | 2005-05-27 | 2011-04-26 | Actelion Pharmaceuticals Ltd | Novel piperidine carboxylic acid amide derivatives |
| RU2425032C2 (ru) * | 2006-02-02 | 2011-07-27 | Актелион Фармасьютикалз Лтд | Вторичные амины в качестве ингибиторов ренина |
| US8129538B1 (en) | 2007-03-28 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| CA2688057A1 (en) | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd. | Novel case of renin inhibitors |
| WO2009023964A1 (en) | 2007-08-20 | 2009-02-26 | Merck Frosst Canada Ltd. | Renin inhibitors |
| JP2011505388A (ja) * | 2007-12-04 | 2011-02-24 | メルク フロスト カナダ リミテツド | レニン阻害剤 |
| JP4790871B2 (ja) | 2008-05-05 | 2011-10-12 | メルク フロスト カナダ リミテツド | レニン阻害剤としての３，４−置換ピペリジン誘導体 |
| EP2467385A4 (en) * | 2009-08-18 | 2013-01-16 | Merck Canada Inc | INHIBITORS OF REINE |
| MX2014011648A (es) * | 2012-03-29 | 2014-10-24 | Toray Industries | Derivado de acido nipecotico y el uso del mismo para propositos medicos. |
| JP6850730B2 (ja) * | 2015-11-12 | 2021-03-31 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| US20230348366A1 (en) | 2020-10-01 | 2023-11-02 | Bayer Aktiengesellschaft | Benzaldehyde oximes and method for producing same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5175179A (en) * | 1991-09-25 | 1992-12-29 | Pfizer Inc. | Method for treating hypertension |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| IT1295694B1 (it) * | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292426B1 (it) * | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| CN1649870A (zh) * | 2002-04-29 | 2005-08-03 | 埃科特莱茵药品有限公司 | 7－芳基－3,9－二氮杂双环[3.3.1]壬－6－烯衍生物及其在治疗高血压,心血管或肾疾病中作为肾素抑制剂的应用 |
| AU2003229746A1 (en) * | 2002-06-27 | 2004-01-19 | Actelion Pharmaceuticals Ltd | Novel tetrahydropyridine derivatives as renin inhibitors |
| CA2521932A1 (en) * | 2003-04-29 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives |
| TW200513461A (en) * | 2003-10-01 | 2005-04-16 | Speedel Experimenta Ag | Organische verbindungen |
| CN1863773A (zh) * | 2003-10-09 | 2006-11-15 | 埃科特莱茵药品有限公司 | 四氢吡啶衍生物 |
| EP1678176A1 (en) * | 2003-10-13 | 2006-07-12 | Actelion Pharmaceuticals Ltd. | Diazabicyclononene derivatives and their use as renin inhibitors |
| US20070135405A1 (en) * | 2003-10-23 | 2007-06-14 | Olivier Bezencon | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain |
| WO2005054244A2 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain |
| AU2004295091A1 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| CN101010323B (zh) * | 2004-08-25 | 2010-06-16 | 埃科特莱茵药品有限公司 | 作为肾素抑制剂的双环壬烯衍生物 |
| US20080103152A1 (en) * | 2004-12-08 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Novel Diazabicyclononene Derivative |
| ATE514697T1 (de) * | 2005-01-28 | 2011-07-15 | Actelion Pharmaceuticals Ltd | 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck |
| GEP20115206B (en) * | 2005-05-27 | 2011-04-26 | Actelion Pharmaceuticals Ltd | Novel piperidine carboxylic acid amide derivatives |
| JP2009528341A (ja) * | 2006-03-03 | 2009-08-06 | アクテリオン ファーマシューティカルズ リミテッド | 新規一級アミン |
-
2007
- 2007-03-07 NZ NZ571595A patent/NZ571595A/en unknown
- 2007-03-07 TW TW096107955A patent/TW200800897A/zh unknown
- 2007-03-07 AR ARP070100947A patent/AR059886A1/es unknown
- 2007-03-07 BR BRPI0708567-2A patent/BRPI0708567A2/pt not_active Application Discontinuation
- 2007-03-07 JP JP2008557879A patent/JP2009529033A/ja active Pending
- 2007-03-07 CL CL2007000595A patent/CL2007000595A1/es unknown
- 2007-03-07 MX MX2008011340A patent/MX2008011340A/es not_active Application Discontinuation
- 2007-03-07 KR KR1020087024544A patent/KR20090008211A/ko not_active Application Discontinuation
- 2007-03-07 US US12/281,684 patent/US20090062342A1/en not_active Abandoned
- 2007-03-07 CN CNA2007800079492A patent/CN101395149A/zh active Pending
- 2007-03-07 EP EP07713218A patent/EP1994026A2/en not_active Withdrawn
- 2007-03-07 CA CA002642436A patent/CA2642436A1/en not_active Abandoned
- 2007-03-07 AU AU2007224368A patent/AU2007224368A1/en not_active Abandoned
- 2007-03-07 WO PCT/IB2007/050758 patent/WO2007102127A2/en active Application Filing
-
2008
- 2008-09-04 IL IL193885A patent/IL193885A0/en unknown
- 2008-09-30 MA MA31266A patent/MA30296B1/fr unknown
- 2008-10-07 ZA ZA200808540A patent/ZA200808540B/xx unknown
- 2008-10-07 NO NO20084186A patent/NO20084186L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090062342A1 (en) | 2009-03-05 |
| ZA200808540B (en) | 2009-12-30 |
| WO2007102127A2 (en) | 2007-09-13 |
| JP2009529033A (ja) | 2009-08-13 |
| CL2007000595A1 (es) | 2008-01-04 |
| CN101395149A (zh) | 2009-03-25 |
| IL193885A0 (en) | 2009-09-22 |
| NZ571595A (en) | 2010-06-25 |
| AU2007224368A1 (en) | 2007-09-13 |
| KR20090008211A (ko) | 2009-01-21 |
| TW200800897A (en) | 2008-01-01 |
| NO20084186L (no) | 2008-10-07 |
| BRPI0708567A2 (pt) | 2011-05-31 |
| MA30296B1 (fr) | 2009-03-02 |
| WO2007102127A3 (en) | 2008-04-03 |
| MX2008011340A (es) | 2008-09-12 |
| CA2642436A1 (en) | 2007-09-13 |
| EP1994026A2 (en) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059886A1 (es) | Derivados de amidas como inhibidores de renina | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| ES2678086T3 (es) | Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| AR062499A1 (es) | Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos. | |
| AR059284A1 (es) | Derivados de aminas secundarias | |
| PE20091426A1 (es) | Compuestos de piridina | |
| AR049418A1 (es) | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR066524A1 (es) | Azetidinas, composiciones farmaceuticas que las comprenden y uso como antagonistas de ep2 | |
| CU20100157A7 (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR052370A1 (es) | Tiazolidinonas y su uso como inhibidores de la poloquinasa(plk) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |